ArthroCare Facing Tough Times

ArthroCare Corp. (ARTC - Analyst Report) develops, manufactures, and markets products based on their patented Coblation technology. Coblation combines bipolar radiofrequency energy with a saline solution to gently and precisely remove soft tissue at low temperatures, which operate at lower temperatures than electrosurgical or laser surgery tools.

The near-term should be difficult for ARTC investors as the company navigates the delayed filing of financial statements, FBI probe, and class action suits. The company's clear strategy to leverage Coblation technology and other innovative, clinically superior surgical devices for the surgical treatment of soft-tissue conditions should help pull them through this difficult time.

New products in Sports Medicine are stimulating growth in a fairly mature segment. Oncology represents another growth opportunity for ARTC.

Recent news is casts a very dark light on the near-term performance of this stock in light of the recent economic situation. ARTC s common stock was delisted from the NASDAQ stock market and is now trading under the symbol ARTC.PK. The stock moves to a long-term Sell.